Happy Sunday!
Since voters created the Cancer Prevention and Research Institute of Texas in 2007, more than a billion dollars of its funding has gone toward recruiting scientists to the state, 362 of them so far across 20 institutions. On Wednesday the board approved twelve more recruitment grants as part of $35 million in awards, with three of the new arrivals headed to UT Austin. Their specialties run from liver and brain cancer to AI-driven lab-on-a-chip detection. The same meeting created a new advisory committee on artificial intelligence.
Private capital spent the week in the same area. Roughly $185 million of the $242 million raised across Texas went to health and life sciences, most of it to Happy Health, which came out of stealth with $75 million behind an FDA-cleared ring that diagnoses sleep apnea in three nights. Astromech in Dallas took $20 million at a $3.8 billion valuation, nearly double where it stood in March, on a plan to forecast where biology breaks before it does.
This week’s full roundup follows an update from pH Partners on another deal in this sector: TYBR Health’s recent raise.
TYBR Health: $30M Series A Financing
Last month, TYBR Health raised a $30M Series A, co-led by Vensana Capital and Mutual Capital Partners. The round brings total funding to approximately $38.7M and will support commercialization and clinical studies for B3 GEL, its FDA-cleared hydrogel for protecting soft tissue after orthopedic surgery.
TYBR received FDA 510(k) clearance in June 2025, began an Australian clinical study in September, and completed its first U.S. procedure in January 2026. This is therefore less a product development round and more a bet that TYBR can turn early surgeon interest into repeated use while building evidence.
B3 GEL is a collagen-based extracellular matrix hydrogel that degrades within 30 days. It is applied around tendons, ligaments, and muscles at the end of surgery, creating a temporary barrier that prevents them from reattaching to nearby tissue as they heal, which can restrict movement, prolong healing, and require another surgery.
B3 GEL was cleared based on substantial equivalence to existing products, principally fellow Texas based company Alafair Biosciences’ VersaWrap, rather than a controlled human trial showing better functional outcomes. TYBR’s current clinical work must now demonstrate that improved range of motion in animal models translates into less stiffness, shorter rehabilitation, or fewer repeat procedures in patients.
The commercial differentiation is also narrower than “flowable hydrogel” alone. Alafair received clearance for its own flowable product, VersaCoat, in July 2025. TYBR’s advantage will need to come from easier application, stronger outcomes, and broader indications that its collagen-based extracellular matrix produces a meaningful benefit.
The investor group also provides some useful strategic context. Vensana led a $20M investment in Artelon in 2023 to fund commercial growth, clinical research, and new indications before the company was acquired by Stryker. Former Artelon CEO, Aaron Smith, now serves as an independent director at TYBR, and Jeff Tyber, who has built and sold several orthopedic device businesses, joined the board earlier this year. Their involvement gives TYBR a team that has already taken similar products from early commercialization through strategic acquisition.
TYBR’s positioning goes beyond creating a physical barrier for healing; it may also influence the inflammatory response that causes excessive scar formation, giving B3 GEL both a mechanical and potential biological role in healing. This combination can differentiate B3 GEL from existing barriers and hydrogels. That advantage remains largely supported by preclinical evidence, making human clinical outcomes the next important proof point to look for.
—Analysis by the pH Partners Team
pH Partners is an Austin-based boutique investment bank focused on Healthcare, Technology, and Consumer markets. Learn more at phpartners.com.
Austin
Happy Health, a developer of an FDA-cleared smart ring for at-home sleep apnea diagnosis, raised $75M in a Series A co-led by ARCH Venture Partners and OpenLoop. $135M raised to date.
Network Bio, a developer of disease-specific AI models trained on human tissue and clinical data, raised $50M in a launch financing led by Section 32 with participation from Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, JSL Health Capital, and others. $50M raised to date.
Boom, a provider of an AI-native leasing and screening platform for rental property managers, raised $15M in a Series A led by S3 Ventures with participation from Mischief, Starting Line, Company Ventures, and Gilgamesh Ventures. $20.50M raised to date.
Synthefy, a developer of foundation models for structured and time-series numerical data, raised $6.50M in a Seed led by Wing Venture Capital with participation from Samsung Next, Canonical, Haystack, and Lightscape. $6.50M raised to date.
Greater Texas Market
Astromech (Dallas), a developer of AI models that predict evolutionary and genomic change in living systems, raised $20M at a $3.8B valuation in a deal led by Bob Nelsen with participation from PEAK6 Investments, Builders VC, CAZ Investments, and NeoGenesis Capital. $60M raised to date.
McGregor Bancshares (McGregor), the holding company for TFNB, a provider of community banking, lending, and trust services in Central Texas, raised $15.45M in a deal from undisclosed investors placed by Hillworth Bank Partners. $66.57M raised to date.
Ours Privacy (Houston), a provider of a HIPAA-compliant customer data platform for healthcare marketers, raised $15M in a Series A co-led by Lightbank and Health Velocity Capital with participation from Rock Health, TMV, Lakehouse, Switch Ventures, Starfire Ventures, GreyMatter, and others. $20M raised to date.
ProbablyMonsters (Fort Worth), a developer of AAA video games through a family of independent studios, raised $10M in the first close of a $50M offering from an undisclosed investor. $260M raised to date.
See you next week!
—Mason & Joel
This edition was supported by Malik Osumah.
Subscribe to Joel Trammell’s CEO Newsletter, Managing the Future.